BeiGene’s (BGNE) BTK-targeting chimeric degradation activation compound designed to degrade wildtype BTK and multiple mutant forms received FDA orphan designation in treatment of Waldenstrom macroglobulinemia, according to a post on the agency’s site.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BGNE: